Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 2/2019

01-02-2019

Venous thromboembolism in patients with cancer undergoing surgical exploration

Authors: Samantha M. Ruff, Kathryn T. Weber, Adam Khader, Charles Conte, Alan Kadison, James Sullivan, John Wang, Raza Zaidi, Gary B. Deutsch

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2019

Login to get access

Abstract

Malignancy and surgery are both independent risk factors for venous thromboembolism (VTE) events. The current NCCN guidelines recommend VTE prophylaxis for up to 28 days after major abdominal or pelvic surgery for malignancy. We set out to evaluate the rate and timing of VTEs among patients with gastric, pancreatic, colorectal, and gynecologic malignancies who underwent surgery. We performed a retrospective review of the NSQIP database (2005–2013) focusing on patients with gastric, colorectal, pancreatic, and gynecologic malignancies. Our primary endpoint was a diagnosis of VTE within 30 days of surgery. We analyzed 128,864 patients in this study. On multivariable analysis, patients with pre-operative sepsis (OR 2.36, CI 2.04–2.76, p < 0.001), disseminated cancer (OR 1.73, CI 1.55–1.92, p < 0.001), congestive heart failure (OR 1.69, CI 1.25–2.28, p = 0.001), gastric cancer (OR 1.3, CI 1.09–1.56, p = 0.004), and pancreatic cancer (OR 1.2, CI 1.03–1.30, p = 0.021) were more likely to have a VTE. Of patients who had a VTE event, 34% occurred after discharge from surgery (gastric: 25%, colorectal 34%, pancreatic 31%, gynecologic malignancy 42%). Our study demonstrates that patients who undergo an operation for malignancy with pre-operative sepsis, disseminated cancer, congestive heart failure, gastric cancer, or pancreatic cancer are more likely to develop a VTE within 30 days of their operation. Of those patients who developed a VTE, approximately one-third occurred after discharge during a 30 day post-operative period. This data supports that further studies are needed to determine the appropriate length of post-operative VTE chemoprophylaxis in patients with cancer.
Literature
1.
go back to reference Heit JA (2015) Epidemiology of venous thromboembolism. Nat Rev: Cardiol 12:464–474 Heit JA (2015) Epidemiology of venous thromboembolism. Nat Rev: Cardiol 12:464–474
2.
go back to reference Khorana AA, Francis CW, Culakova E et al (2007) Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110:2339–2346CrossRefPubMed Khorana AA, Francis CW, Culakova E et al (2007) Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110:2339–2346CrossRefPubMed
3.
go back to reference Khorana AA (2009) Cancer and thrombosis: implications of published guidelines for clinical practice. Ann Oncol 20:1619–1630CrossRefPubMed Khorana AA (2009) Cancer and thrombosis: implications of published guidelines for clinical practice. Ann Oncol 20:1619–1630CrossRefPubMed
4.
go back to reference Dobesh PP (2009) Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy 29:943–953CrossRefPubMed Dobesh PP (2009) Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy 29:943–953CrossRefPubMed
5.
go back to reference Tesselaar ME, Romijn FP, Van Der Linden IK et al (2007) Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 5:520–527CrossRefPubMed Tesselaar ME, Romijn FP, Van Der Linden IK et al (2007) Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 5:520–527CrossRefPubMed
7.
go back to reference Mandala M, Reni M, Cascinu S et al (2007) Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 18:1660–1665CrossRefPubMed Mandala M, Reni M, Cascinu S et al (2007) Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 18:1660–1665CrossRefPubMed
8.
go back to reference Galster H, Kolb G, Kohsytorz A et al (2000) The pre-, peri-, and postsurgical activation of coagulation and the thromboembolic risk for different risk groups. Thromb Res 100:381–388CrossRefPubMed Galster H, Kolb G, Kohsytorz A et al (2000) The pre-, peri-, and postsurgical activation of coagulation and the thromboembolic risk for different risk groups. Thromb Res 100:381–388CrossRefPubMed
9.
go back to reference Gallus AS (1997) Prevention of post operative deep leg vein thrombosis in patients with cancer. Thromb Haemost 78:126–132CrossRefPubMed Gallus AS (1997) Prevention of post operative deep leg vein thrombosis in patients with cancer. Thromb Haemost 78:126–132CrossRefPubMed
10.
go back to reference Lyman GH, Khorana AA, Falanga A et al (2007) American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490–5505CrossRefPubMed Lyman GH, Khorana AA, Falanga A et al (2007) American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490–5505CrossRefPubMed
11.
go back to reference Mandala M, Falanga A, Roila F (2008) Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 19:ii126–i7CrossRefPubMed Mandala M, Falanga A, Roila F (2008) Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 19:ii126–i7CrossRefPubMed
12.
go back to reference Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians evidence based clinical practice guidelines (8th edn). Chest 133:381S–453SCrossRefPubMed Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians evidence based clinical practice guidelines (8th edn). Chest 133:381S–453SCrossRefPubMed
14.
go back to reference Khalil J, Bensaid B, Elkacemi H et al (2015) Venous thromboembolism in cancer patients: an underestimated major health problem. World J Surg Oncol 13:204CrossRefPubMedPubMedCentral Khalil J, Bensaid B, Elkacemi H et al (2015) Venous thromboembolism in cancer patients: an underestimated major health problem. World J Surg Oncol 13:204CrossRefPubMedPubMedCentral
15.
go back to reference Khorana AA, Dalal M, Lin J et al (2013) Incidence and predictors of venous thromboembolism (VTE) among ambulatory high risk cancer patients undergoing chemotherapy in the United States. Cancer 119:648–655CrossRefPubMed Khorana AA, Dalal M, Lin J et al (2013) Incidence and predictors of venous thromboembolism (VTE) among ambulatory high risk cancer patients undergoing chemotherapy in the United States. Cancer 119:648–655CrossRefPubMed
17.
go back to reference Ansari D, Ansari D, Andersson R et al (2015) Pancreatic cancer and thromboembolic disease, 150 years after Trousseau. Hepatobiliary Surg Nutr 4:325–335PubMedPubMedCentral Ansari D, Ansari D, Andersson R et al (2015) Pancreatic cancer and thromboembolic disease, 150 years after Trousseau. Hepatobiliary Surg Nutr 4:325–335PubMedPubMedCentral
18.
go back to reference Kessler CM (2009) The link between cancer and venous thromboembolism: a review. Am J Clin Oncol 32(4):S3–S7CrossRefPubMed Kessler CM (2009) The link between cancer and venous thromboembolism: a review. Am J Clin Oncol 32(4):S3–S7CrossRefPubMed
19.
go back to reference Khorana AA, Dalal M, Tangirala K et al (2011) Higher incidence of venous thromboembolism in outpatient versus the inpatient setting among US cancer patients. Blood 118:674 Khorana AA, Dalal M, Tangirala K et al (2011) Higher incidence of venous thromboembolism in outpatient versus the inpatient setting among US cancer patients. Blood 118:674
20.
go back to reference Agnelli G, Bolis G, Capussotti L et al (2006) A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 243:89–95CrossRefPubMedPubMedCentral Agnelli G, Bolis G, Capussotti L et al (2006) A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 243:89–95CrossRefPubMedPubMedCentral
22.
go back to reference Qureshi W, Ali Z, Amjad W et al (2016) Venous thromboembolism in cancer: an update of treatment and prevention in the era of newer anticoagulants. Front Cardiovasc Med 3:24CrossRefPubMedPubMedCentral Qureshi W, Ali Z, Amjad W et al (2016) Venous thromboembolism in cancer: an update of treatment and prevention in the era of newer anticoagulants. Front Cardiovasc Med 3:24CrossRefPubMedPubMedCentral
23.
go back to reference Cain K, Schmeler K, Langley G et al (2012) Patient cost associated with filling a prescription for extended duration venous thromboembolism (VTE) prophylaxis following surgery for gynecologic cancer. Gynecol Oncol 127(1):18–21CrossRefPubMed Cain K, Schmeler K, Langley G et al (2012) Patient cost associated with filling a prescription for extended duration venous thromboembolism (VTE) prophylaxis following surgery for gynecologic cancer. Gynecol Oncol 127(1):18–21CrossRefPubMed
24.
go back to reference Merkow RP, Bilimoria KY, McCarter MD et al (2011) Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg 254:131–137CrossRefPubMed Merkow RP, Bilimoria KY, McCarter MD et al (2011) Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg 254:131–137CrossRefPubMed
25.
go back to reference Iversen LH, Thorlacius-Ussing O (2002) Relations of coagulation test abnormalities to tumour burden and postoperative DVT in resected colorectal cancer. Thromb Haemost 87:402–408CrossRefPubMed Iversen LH, Thorlacius-Ussing O (2002) Relations of coagulation test abnormalities to tumour burden and postoperative DVT in resected colorectal cancer. Thromb Haemost 87:402–408CrossRefPubMed
26.
go back to reference Rickles FR (2006) Mechanisms of cancer induced thrombosis. J Pathophysiol Haemost Thromb 35:103–110CrossRef Rickles FR (2006) Mechanisms of cancer induced thrombosis. J Pathophysiol Haemost Thromb 35:103–110CrossRef
27.
go back to reference Abdol Razak NB, Jones G, Bhandari M et al (2018) Cancer associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers 10(10):380CrossRefPubMedCentral Abdol Razak NB, Jones G, Bhandari M et al (2018) Cancer associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers 10(10):380CrossRefPubMedCentral
28.
go back to reference Lee AY, Levine MN (2003) Venous thromboembolism and cancer: risks and outcomes. Circulation 107:117–121 Lee AY, Levine MN (2003) Venous thromboembolism and cancer: risks and outcomes. Circulation 107:117–121
29.
go back to reference Neoptolemos JP, Palmer DH, Ghaneh P et al (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicenter, open-label, randomized phase 3 trial. Lancet 389:1011–1024CrossRefPubMed Neoptolemos JP, Palmer DH, Ghaneh P et al (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicenter, open-label, randomized phase 3 trial. Lancet 389:1011–1024CrossRefPubMed
30.
go back to reference Martino MA, Borges E, Wiliammson E et al (2006) Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol 107:666–671CrossRefPubMed Martino MA, Borges E, Wiliammson E et al (2006) Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol 107:666–671CrossRefPubMed
31.
go back to reference Bergqvist D, Agnelli G, Cohen AT et al (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346:975–980CrossRefPubMed Bergqvist D, Agnelli G, Cohen AT et al (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346:975–980CrossRefPubMed
32.
go back to reference Rasmussen MS, Jorgensen LN, Wille-Jorgensen P et al (2006) Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 4:2384–2390CrossRefPubMed Rasmussen MS, Jorgensen LN, Wille-Jorgensen P et al (2006) Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 4:2384–2390CrossRefPubMed
34.
go back to reference Petch S, Norris L, O’Toole S et al (2016) Peri operative venous thromboembolism prophylaxis in gynaecological cancer patients. A survey of current practice. Thromb Res 145:126–128CrossRefPubMed Petch S, Norris L, O’Toole S et al (2016) Peri operative venous thromboembolism prophylaxis in gynaecological cancer patients. A survey of current practice. Thromb Res 145:126–128CrossRefPubMed
35.
go back to reference Kakkar VV, Balibrea JL, Martinez-Gonzalez J et al (2010) Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 8(6):1223–1229CrossRefPubMed Kakkar VV, Balibrea JL, Martinez-Gonzalez J et al (2010) Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 8(6):1223–1229CrossRefPubMed
36.
37.
go back to reference Donze JD, Ridker PM, Finlayson SRG et al (2014) Impact of sepsis on risk of postoperative arterial and venous thromboses: large prospective cohort study. BMJ 349:5334CrossRef Donze JD, Ridker PM, Finlayson SRG et al (2014) Impact of sepsis on risk of postoperative arterial and venous thromboses: large prospective cohort study. BMJ 349:5334CrossRef
38.
go back to reference Schmeler KM, Langley G, Cain K et al (2013) Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies. Gynecol Oncol 128:204–208CrossRef Schmeler KM, Langley G, Cain K et al (2013) Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies. Gynecol Oncol 128:204–208CrossRef
Metadata
Title
Venous thromboembolism in patients with cancer undergoing surgical exploration
Authors
Samantha M. Ruff
Kathryn T. Weber
Adam Khader
Charles Conte
Alan Kadison
James Sullivan
John Wang
Raza Zaidi
Gary B. Deutsch
Publication date
01-02-2019
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2019
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-018-1774-3

Other articles of this Issue 2/2019

Journal of Thrombosis and Thrombolysis 2/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.